Solution

Demodex spp. contribute to the development of chronic blepharitis and other diseases such as dry eye syndrome, rosacea, etc. Chronic Demodex-related blepharitis can be observed in ~5% of the human population and its prevalence increases with age.

To date, there are no Demodex-targeted medicinal products approved in the EU, and the existing cosmetic products are not effective.

TG Pharma develops an easy-to-apply medicinal product based on a known compound - permethrin, an acaricide and insecticide. Our aim is to repurpose the active ingredient which is already used in humans to treat scabies, amongst others.

The company has applied for patent protection and will start product formulation development in the second half of 2024.